Thrombotic Thrombocytopenic Purpura: A Thrombotic Disorder Caused by ADAMTS13 Deficiency

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 609-632

  Tsai, Han Mou ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; POLYMER; PROSTACYCLIN DERIVATIVE; RITUXIMAB; SHIGA TOXIN; THROMBOSPONDIN; TICLOPIDINE; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADAMTS13 DEFICIENCY; BACTERIAL INFECTION; CHROMOSOME 9Q; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYOPRECIPITATE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; DNA SEQUENCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME DEFICIENCY; ENZYME STRUCTURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC DISORDER; GLYCOSYLATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MICROTHROMBUS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PLASMAPHERESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SHEAR STRESS; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AUTOANTIBODIES; DISEASE MANAGEMENT; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 34547114993     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.003     Document Type: Review

References (105)

1. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med 36 1 (1925) 89-93
2. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325 6 (1991) 393-397
3. Tapper D., Tarr P., Avner E., et al. Lessons learned in the management of hemolytic uremic syndrome in children. J Pediatr Surg 30 2 (1995) 158-163
4. Vesely S.K., George J.N., Lammle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102 1 (2003) 60-68
5. Remuzzi G., Galbusera M., Noris M., et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100 3 (2002) 778-785
6. Bukowski R.M. Thrombocytopenic purpura. A review. Prog Hemost Thromb 6 1 (1982) 287-337
7. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 6855 (2001) 488-494
8. Soejima K., Mimura N., Hirashima M., et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem (Tokyo) 130 4 (2001) 475-480
9. Zheng X., Chung D., Takayama T.K., et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 44 (2001) 41059-41063
10. Zhou W., Inada M., Lee T.P., et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 85 6 (2005) 780-788
11. Uemura M., Tatsumi K., Matsumoto M., et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 106 3 (2005) 922-924
12. Suzuki M., Murata M., Matsubara Y., et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 313 1 (2004) 212-216
13. Liu L., Choi H., Bernardo A., et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 3 11 (2005) 2536-2544
14. Turner N., Nolasco L., Tao Z., et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 4 6 (2006) 1396-1404
15. Tsai H.M., Sussman I.I., Ginsburg D., et al. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 89 6 (1997) 1954-1962
16. Crawley J.T. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 105 3 (2005) 1085-1093
17. Studt J.D., Hovinga J.A., Antoine G., et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 105 2 (2005) 542-544
18. Bonnefoy A., Daenens K., Feys H.B., et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood 107 3 (2006) 955-964
19. Apte S.S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 36 6 (2004) 981-985
20. Nicholson A.C., Malik S.B., Logsdon Jr. J.M., et al. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 5 1 (2005) 11. http://www.biomedcentral.com/1471-2148/5/11 Available at: http://www.biomedcentral.com/1471-2148/5/11.
21. Majerus E.M., Zheng X., Tuley E.A., et al. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 278 47 (2003) 46643-46648
22. Zhou W., Dong L., Ginsburg D., et al. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?. J Biol Chem 280 48 (2005) 39934-39941
23. Zheng X., Nishio K., Majerus E.M., et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 278 32 (2003) 30136-30141
24. Soejima K., Matsumoto M., Kokame K., et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 102 9 (2003) 3232-3237
25. Gao W., Anderson P.J., Majerus E.M., et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 103 50 (2006) 19099-19104
26. Luken B.M., Turenhout E.A., Hulstein J.J., et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 93 2 (2005) 267-274
27. Klaus C., Plaimauer B., Studt J.D., et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 103 12 (2004) 4514-4519
28. Tsai H.M. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 29 5 (2003) 479-488
29. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 22 (1998) 1585-1594
30. Ruggeri Z.M., Orje J.N., Habermann R., et al. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 108 6 (2006) 1903-1910
31. Weiss H.J., Turitto V.T., and Baumgartner H.R. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med 92 5 (1978) 750-764
32. Chauhan A.K., Motto D.G., Lamb C.B., et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 203 3 (2006) 767-776
33. Dong J.F., Moake J.L., Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100 12 (2002) 4033-4039
34. Motto D.G., Chauhan A.K., Zhu G., et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 115 10 (2005) 2752-2761
35. Furlan M., Robles R., Solenthaler M., et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91 8 (1998) 2839-2846
36. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 22 (1998) 1578-1584
37. Tsai H.M., Raoufi M., Zhou W., et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 95 5 (2006) 886-892
38. Zhou W., and Tsai H.M. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 91 4 (2004) 806-811
39. Rick M.E., Moll S., Taylor M.A., et al. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 88 4 (2002) 598-604
40. Veyradier A., Obert B., Houllier A., et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98 6 (2001) 1765-1772
41. Bohm M., Vigh T., and Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 81 8 (2002) 430-435
42. Hovinga J.A., Studt J.D., Alberio L., et al. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 41 1 (2004) 75-82
43. Matsumoto M., Yagi H., Ishizashi H., et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 41 1 (2004) 68-74
44. Coppo P., Bengoufa D., Veyradier A., et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83 4 (2004) 233-244
45. Terrell D.R., Williams L.A., Vesely S.K., et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 3 7 (2005) 1432-1436
46. Peyvandi F., Ferrari S., Lavoretano S., et al. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 127 4 (2004) 433-439
47. Kokame K., Nobe Y., Kokubo Y., et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129 1 (2005) 93-100
48. Zheng X.L., Kaufman R.M., Goodnough L.T., et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103 11 (2004) 4043-4049
49. Uemura M., Matsuyama T., Ishikawa M., et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 29 Suppl 12 (2005) 264S-271S
50. Ono T., Mimuro J., Madoiwa S., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107 2 (2006) 528-534
51. Nguyen T.C., Liu A., Liu L., et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 92 1 (2007) 121-124
52. Bianchi V., Robles R., Alberio L., et al. Von von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100 2 (2002) 710-713
53. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 44 1 (2006) 53-61
54. Banno F., Kokame K., Okuda T., et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 107 8 (2006) 3161-3166
55. Torok T.J., Holman R.C., and Chorba T.L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968-1991. Am J Hematol 50 2 (1995) 84-90
56. Miller D.P., Kaye J.A., Shea K., et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 15 2 (2004) 208-215
57. Schech S.D., Brinker A., Shatin D., et al. New-onset and idiopathic thrombotic thrombocytopenic purpura: incidence, diagnostic validity, and potential risk factors. Am J Hematol 81 9 (2006) 657-663
58. Hymes K.B., and Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy. Semin Hematol 34 2 (1997) 117-125
59. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128 7 (1998) 541-544
60. Tsai H.M., Rice L., Sarode R., et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 132 10 (2000) 794-799
61. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 24 (2000) 1773-1777
62. Zakarija A., Bandarenko N., Pandey D.K., et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 35 2 (2004) 533-537
63. Ridolfi R.L., Hutchins G.M., and Bell W.R. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med 91 3 (1979) 357-363
64. Podolsky S.H., Zembowicz A., Schoen F.J., et al. Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med 123 10 (1999) 937-940
65. Downes K.A., Yomtovian R., Tsai H.M., et al. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apheresis 19 2 (2004) 86-89
66. Kennedy S.S., Zacharski L.R., and Beck J.R. Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases. Semin Thromb Hemost 6 4 (1980) 341-349
67. Mannucci P.M., Vanoli M., Forza I., et al. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88 8 (2003) 914-918
68. Sill H., Hofler G., Kaufmann P., et al. Angiotropic large cell lymphoma presenting as thrombotic microangiopathy (thrombotic thrombocytopenic purpura). Cancer 75 5 (1995) 1167-1170
69. Lin Y.C., Chang H.K., Sun C.F., et al. Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J 88 6 (1995) 683-687
70. Fontana S., Gerritsen H.E., Kremer H.J., et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 113 1 (2001) 100-102
71. Forman R.B., Benkel S.A., Novik Y., et al. Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy. Acta Haematol 109 3 (2003) 150-152
72. Sinha A., and Rai R. Haemolytic uraemic syndrome following acute pancreatitis. JOP 6 4 (2005) 365-368
73. Moake J.L., and McPherson P.D. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 87 3N (1989) 9N-15N
74. Tsai H.M., Chandler W.L., Sarode R., et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 49 5 (2001) 653-659
75. Veyradier A., Nishikubo T., Humbert M., et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 102 20 (2000) 2460-2462
76. Vincentelli A., Susen S., Le T.T., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349 4 (2003) 343-349
77. Tripodi A., Chantarangkul V., Bohm M., et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2 9 (2004) 1601-1609
78. Rieger M., Ferrari S., Kremer Hovinga J.A., et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 95 2 (2006) 212-220
79. Shelat S.G., Smith P., Ai J., et al. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 4 8 (2006) 1707-1717
80. Tsai H.M., Li A., and Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 47 7-8 (2001) 387-392
81. Rieger M., Mannucci P.M., Hovinga J.A., et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106 4 (2005) 1262-1267
82. Byrnes J.J., Moake J.L., Klug P., et al. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 34 3 (1990) 169-174
83. Yarranton H., Lawrie A.S., Purdy G., et al. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 1 (2004) 39-44
84. Scott E.A., Puca K.E., Pietz B.C., et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 47 1 (2007) 120-125
85. Allford S.L., Harrison P., Lawrie A.S., et al. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 111 4 (2000) 1215-1222
86. Zeigler Z.R., Shadduck R.K., Gryn J.F., et al. Cryoprecipitate-poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apheresis 16 1 (2001) 19-22
87. Rock G., Anderson D., Clark W., et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 129 1 (2005) 79-86
88. Tsai H.M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87 10 (1996) 4235-4244
89. Bobbio-Pallavicini E., Gugliotta L., Centurioni R., et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 82 4 (1997) 429-435
90. Allford S.L., Hunt B.J., Rose P., et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120 4 (2003) 556-573
91. George J.N., Woodson R.D., Kiss J.E., et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 21 1 (2006) 49-56
92. Cataland S.R., and Wu H.M. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 12 5 (2005) 359-363
93. Wyllie B.F., Garg A.X., Macnab J., et al. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 132 2 (2006) 204-209
94. Vesely S.K., Li X., McMinn J.R., et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 44 8 (2004) 1149-1158
95. Lattuada A., Rossi E., Calzarossa C., et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88 9 (2003) 1029-1034
96. Sanchez-Luceros A., Farias C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 92 6 (2004) 1320-1326
97. Schulman I., Pierce M., Lukens A., et al. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 16 7 (1960) 943-957
98. Upshaw Jr. J.D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 298 24 (1978) 1350-1352
99. Tsai H.M. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 57 (2006) 419-436
100. Plaimauer B., Fuhrmann J., Mohr G., et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 107 1 (2006) 118-125
101. Shibagaki Y., Matsumoto M., Kokame K., et al. Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant 21 5 (2006) 1289-1292
102. Tao Z., Anthony K., Peng Y., et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 4 9 (2006) 1931-1935
103. Donadelli R., Banterla F., Galbusera M., et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 96 4 (2006) 454-464
104. Schneppenheim R., Kremer Hovinga J.A., Becker T., et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 96 1 (2006) 3-6
105. Noris M., Bucchioni S., Galbusera M., et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 16 5 (2005) 1177-1183